June 23, 2021 -- Digital biology company Recursion signed a multiyear deal with artificial intelligence (AI) research institute Mila to develop technology-enabled drug discovery.
Recursion leverages machine learning to unravel complex patterns of biology within biological datasets of more than 8 PB.
Under the deal, Recursion will open office space within Mila and build a team to improve its machine-learning capabilities. Mila's AI technology and experts will help Recursion improve the lives of patients while industrializing drug discovery.
Financial details of the collaboration were not disclosed.